A clinical trial to determine if AIC263029 is safe when dosed only once or several times, and to investigate how it moves within the human body
Phase 1
- Conditions
- BKV-associated nephropathyMedDRA version: 20.0Level: HLGTClassification code: 10047438Term: Viral infectious disorders Class: 10021881MedDRA version: 20.0Level: SOCClassification code: 10021881Term: Infections and infestations Class: 1MedDRA version: 20.1Level: LLTClassification code: 10065333Term: BK virus nephropathy Class: 10021881MedDRA version: 20.1Level: PTClassification code: 10065381Term: Polyomavirus-associated nephropathy Class: 100000004862MedDRA version: 20.0Level: HLTClassification code: 10057200Term: Polyomavirus infections Class: 10021881Therapeutic area: Diseases [C] - Virus Diseases [C02]
- Registration Number
- CTIS2023-510074-13-00
- Lead Sponsor
- AiCuris Anti-infective Cures AG
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 72
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method